{"raw_mentions": "There are no sentences in the provided text that meet the specified criteria. The text appears to be a background introduction to the invention and does not contain specific bioactivity metrics with numeric values and units."}
{"raw_mentions": "There are no sentences in the provided text that contain all of the following:\n1. A bioactivity metric (IC50, Ki, Kd, EC50).\n2. A specific numeric value associated with that metric (e.g., \"10\", \"5.5\", \"<100\").\n3. A unit for that value (e.g., \"nM\", \"uM\", \"%\").\n\nTherefore, there are no sentences to return."}
{"raw_mentions": "Preferably, the compounds of the instant invention inhibit FPTase in vitro (Example 19) at an IC50 of less than 100 nM and inhibit GGTase-I in vitro (Example 20) at an IC50 of less than 5 \u03bcM.\nAlso preferably, the compounds of the instant invention inhibit the cellular processing of the hDJ protein (Example 24) at an EC50 of less than about 250 nM.\nAlso preferably, the compounds of the instant invention inhibit the cellular processing of the Rap1 protein (Example 25) at an EC50 of less than about 10 \u03bcM.\nMore preferably, the compounds of the instant invention inhibit the cellular processing of the Rap1 protein (Example 25) at an EC50 of less than about 1 \u03bcM."}
{"final_json": [{"molecule_name": "compounds of the instant invention", "protein_target_name": "FPTase", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "<100", "unit": "nM"}, {"molecule_name": "compounds of the instant invention", "protein_target_name": "GGTase-I", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "<5", "unit": "\u03bcM"}, {"molecule_name": "compounds of the instant invention", "protein_target_name": "hDJ protein", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<250", "unit": "nM"}, {"molecule_name": "compounds of the instant invention", "protein_target_name": "Rap1 protein", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<10", "unit": "\u03bcM"}, {"molecule_name": "compounds of the instant invention", "protein_target_name": "Rap1 protein", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "EC50", "value": "<1", "unit": "\u03bcM"}]}
{"raw_mentions": "There are no sentences that meet the specified criteria. The text does not contain any sentences with a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value, and a unit for that value."}
{"raw_mentions": "Here are the extracted sentences with concrete data points that meet the specified criteria:\n\n\n[0620] For inhibition studies, assays are run as described above, except inhibitors are prepared as concentrated solutions in 100% dimethyl sulfoxide and then diluted 20-fold into the enzyme assay mixture. Substrate concentrations for inhibitor IC50 determinations are as follows: FTase, 650 nM Ras-CVLS (SEQ.ID.NO.: 1), 100 nM farnesyl diphosphate.\n[0621] The compounds of the instant invention described in the above Examples 1-18 were tested for inhibitory activity against human FPTase by the assay described above and were found to have an IC50 of \u22665 \u03bcM.\n[0623] For inhibition studies, assays are run as described above, except inhibitors are prepared as concentrated solutions in 100% dimethyl sulfoxide and then diluted 25-fold into the enzyme assay mixture. IC50 values are determined with Ras peptide near KM concentrations. Enzyme and substrate concentrations for inhibitor IC50 determinations are as follows: 75 pM GGTase-I, 1.6 \u03bcM Ras peptide, 100 nM geranylgeranyl diphosphate.\n[0624] The compounds of the instant invention described in the above were tested for inhibitory activity against human GGTase-type I by the assay described above and were found to have an IC50 of \u22665 \u03bcM."}
{"final_json": [{"molecule_name": "Ras-CVLS", "protein_target_name": "FTase", "protein_uniprot_id": null, "protein_seq_id": "1", "binding_metric": "IC50", "value": null, "unit": "nM"}, {"molecule_name": "compounds of the instant invention", "protein_target_name": "human FPTase", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "\u22665", "unit": "\u03bcM"}, {"molecule_name": "Ras peptide", "protein_target_name": "GGTase-I", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": null, "unit": "pM"}, {"molecule_name": "compounds of the instant invention", "protein_target_name": "human GGTase-type I", "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": "IC50", "value": "\u22665", "unit": "\u03bcM"}]}
{"raw_mentions": "Here are the extracted sentences with concrete data points that meet the specified criteria:\n\n\nCells treated with lovastatin (5-10 \u03bcM), a compound that blocks Ras processing in cells by inhibiting a rate-limiting step in the isoprenoid biosynthetic pathway, serve as a positive control."}
{"final_json": [{"molecule_name": "lovastatin", "protein_target_name": null, "protein_uniprot_id": null, "protein_seq_id": null, "binding_metric": null, "value": "5-10", "unit": "\u03bcM"}]}
{"raw_mentions": "There are no sentences that contain all of the required elements: a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value associated with that metric, and a unit for that value. The text provided appears to describe experimental methods and protocols, but does not include specific data points with bioactivity metrics and their corresponding values and units."}
{"raw_mentions": "There are no sentences that contain all of the required elements: a bioactivity metric (IC50, Ki, Kd, EC50), a specific numeric value associated with that metric, and a unit for that value. \n\nHowever, one sentence comes close, but it does not include a unit:\n\n\"The Rap1a Minimum Inhibitory Concentration is determined from the lowest concentration of compound that produces a detectable Rap1a Western signal.\"\n\nAnother sentence mentions an EC50 value, but it does not include a specific numeric value or unit:\n\n\"The assay is run as described in Protocol B with the following modifications... The percentage of unprenylated Rap1a relative to the total amount of Rap1a is determined by peak integration using Imagequant\u00ae software (Molecular Dynamics). Unprenylated Rap1a is distinguished from prenylated protein by virtue of the greater apparent molecular weight of the prenylated protein. Dose-response curves and EC50 values are generated using 4-parameter curve fits in SigmaPlot software.\"\n\nSince neither of these sentences meets the criteria, there are no sentences to return."}
